Gerald Luc

Summary

Affiliation: Institut Pasteur de Lille
Country: France

Publications

  1. ncbi The relationship between apolipoprotein AI-containing lipoprotein fractions and environmental factors: the prospective epidemiological study of myocardial infarction (PRIME study)
    G Luc
    Department of Atherosclerosis, SERLIA and INSERM U325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Cedex, Lille, France
    Atherosclerosis 152:399-405. 2000
  2. ncbi Plasma cystatin-C and development of coronary heart disease: The PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille Cedex, France and University Lille II, France
    Atherosclerosis 185:375-80. 2006
  3. ncbi [Inflammation markers and vascular risk]
    G Luc
    Service de Medecine Interne A, CHRU de Lille, Universite de Lille II, France
    Rev Med Interne 25:S7-9. 2004
  4. ncbi Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism
    Gerald Luc
    Department of Atherosclerosis, Institute Pasteur of Lille, France and Faculté de Pharmacie, University Lille II, France
    J Cardiovasc Pharmacol 43:452-3. 2004
  5. ncbi Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille, France
    Atherosclerosis 170:169-76. 2003
  6. ncbi [Antilipemics: results of large studies]
    Gerald Luc
    Departement d Atherosclerose, INSERM UR545, Institut Pasteur de Lille, Service de Medecine Interne A, CHU de Lille, Hopital Huriez, Lille, France
    Therapie 58:23-9. 2003
  7. ncbi C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille and University Lille II, 1 rue du Professeur Calmette, 59019 Lille Cedex, France
    Arterioscler Thromb Vasc Biol 23:1255-61. 2003
  8. ncbi Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, INSERM UR545, Pasteur Institute of Lille, 1, rue du Professeur Calmette, France and University Lille II, France
    Atherosclerosis 163:377-84. 2002
  9. ncbi [Biological banks of the prospective cohort PRIME Study]
    G Luc
    Departement d Atherosclerose, SERLIA INSERM UR545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Rev Epidemiol Sante Publique 51:159-66. 2003
  10. ncbi Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction
    Gerald Luc
    Department of Atherosclerosis, INSERM UR545, Institut Pasteur de Lille, and University Lille II, Lille, France
    Arterioscler Thromb Vasc Biol 22:1155-61. 2002

Collaborators

Detail Information

Publications16

  1. ncbi The relationship between apolipoprotein AI-containing lipoprotein fractions and environmental factors: the prospective epidemiological study of myocardial infarction (PRIME study)
    G Luc
    Department of Atherosclerosis, SERLIA and INSERM U325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Cedex, Lille, France
    Atherosclerosis 152:399-405. 2000
    ....
  2. ncbi Plasma cystatin-C and development of coronary heart disease: The PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille Cedex, France and University Lille II, France
    Atherosclerosis 185:375-80. 2006
    ..Cystatin-C is not a more predictive risk marker of CHD than CRP or interleukin-6, but could be useful in detecting moderate chronic renal disease...
  3. ncbi [Inflammation markers and vascular risk]
    G Luc
    Service de Medecine Interne A, CHRU de Lille, Universite de Lille II, France
    Rev Med Interne 25:S7-9. 2004
  4. ncbi Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism
    Gerald Luc
    Department of Atherosclerosis, Institute Pasteur of Lille, France and Faculté de Pharmacie, University Lille II, France
    J Cardiovasc Pharmacol 43:452-3. 2004
    ....
  5. ncbi Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille, France
    Atherosclerosis 170:169-76. 2003
    ....
  6. ncbi [Antilipemics: results of large studies]
    Gerald Luc
    Departement d Atherosclerose, INSERM UR545, Institut Pasteur de Lille, Service de Medecine Interne A, CHU de Lille, Hopital Huriez, Lille, France
    Therapie 58:23-9. 2003
    ....
  7. ncbi C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, SERLIA INSERM UR545, Institut Pasteur de Lille and University Lille II, 1 rue du Professeur Calmette, 59019 Lille Cedex, France
    Arterioscler Thromb Vasc Biol 23:1255-61. 2003
    ....
  8. ncbi Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study
    Gerald Luc
    Department of Atherosclerosis, INSERM UR545, Pasteur Institute of Lille, 1, rue du Professeur Calmette, France and University Lille II, France
    Atherosclerosis 163:377-84. 2002
    ..This study which analyzed Lp(a) level using a measurement independent of apolipoprotein (a) size on fresh plasma, has confirmed utility of Lp(a) as a predictor of CHD...
  9. ncbi [Biological banks of the prospective cohort PRIME Study]
    G Luc
    Departement d Atherosclerose, SERLIA INSERM UR545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Rev Epidemiol Sante Publique 51:159-66. 2003
    ..However, the high cost of mounting such studies, along with the newer hypotheses generated during the period of follow-up necessitates the use of plasma and serum banks for analyses of many biological parameters...
  10. ncbi Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction
    Gerald Luc
    Department of Atherosclerosis, INSERM UR545, Institut Pasteur de Lille, and University Lille II, Lille, France
    Arterioscler Thromb Vasc Biol 22:1155-61. 2002
    ..We have examined the association between the incidence of coronary heart disease (CHD) and plasma high density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I), and 2 HDL fractions, lipoprotein A-I and lipoprotein A-I:A-II...
  11. doi Lipoprotein(a) plasma levels and the risk of cancer: the PRIME study
    Emilie Marrer
    Department of Epidemiology and Public Health, Faculty of Medicine, University of Strasbourg, Strasbourg, France
    Eur J Cancer Prev 22:286-93. 2013
    ..Further research focusing on the lipoprotein(a) qualitative structure, that is, apolipoprotein(a) polymorphism could help clarify this highly complex relation...
  12. ncbi Fish consumption is associated with lower heart rates
    Jean Dallongeville
    INSERM U 508, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59019 Lille Cedex, France
    Circulation 108:820-5. 2003
    ..Fish consumption decreases risk of sudden death. The goal of the present study was to assess the relationship between fish consumption and heart rate...
  13. ncbi Significant impact of the highly informative (CA)n repeat polymorphism of the APOA-II gene on the plasma APOA-II concentrations and HDL subfractions: The ECTIM study
    Thierry Brousseau
    INSERM Unité 508, Institut Pasteur de Lille, Lille, France
    Am J Med Genet 110:19-24. 2002
    ..These data revive interest in evaluating the role of the APOA-II locus in the control of APOA-II plasma levels and HDL composition...
  14. ncbi Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation
    Hélène Duez
    UR545INSERM, Departement d Atherosclerose, Institut Pasteur Lille and Faculté de Pharmacie, Université de Lille2, France
    Arterioscler Thromb Vasc Biol 25:585-91. 2005
    ..The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I...
  15. ncbi Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene
    Oscar Pérez-Méndez
    Department of Atherosclerosis, INSERM U545, Institut Pasteur de Lille, Lille, France
    Clin Chim Acta 368:149-54. 2006
    ..To verify the role of 2 different LPL gene mutations on HDL metabolism, we studied the in vivo turnover of the apo AI and apo AII in heterozygous carriers of LPL deficiency...
  16. doi Small, qualitative changes in fatty acid intake decrease plasma low-density lipoprotein-cholesterol levels in mildly hypercholesterolemic outpatients on their usual high-fat diets
    Jean Michel Lecerf
    Nutrition Department, Pasteur Institute, Lille, France
    Int J Food Sci Nutr 60:151-63. 2009
    ..The diet is the first step in managing hypercholesterolemia. The objective of the present study is to assess whether moderate changes in dietary fatty acids improve plasma lipid parameters in mildly hypercholesterolemic outpatients...